Back to Trials
NCT06481943Recruiting

A Prospective Research Investigation of Ischemia Using MCG

SB Technology, Inc.

Start Date

7/11/2024

Completion Date

4/1/2026

Summary

PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Scheduled to undergo a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute myocardial infarction * Ability for participant to comply with study requirements * Patient consented before the planned, clinically indicated cath-lab procedure begins to allow sufficient time for study related activities * Written informed consent Exclusion Criteria: * Present STEMI * Pregnant or breastfeeding * Having an active atrial fibrillation episode as seen on most current 12-lead ECG * Active thoracic metal implant * Poor access to follow-up

Interventions

DEVICE

Sponsor MCG device (CardiAQ)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Acute Coronary Syndrome

Locations

Mayo Clinic

Rochester, Minnesota 55905

United States

Mount Sinai Hospital

New York, New York 10029

United States